` DBV (DBV Technologies SA) vs DAX Index Comparison - Alpha Spread

DBV
vs
DAX Index

Over the past 12 months, DBV has underperformed DAX Index, delivering a return of 20% compared to the DAX Index's 30% growth.

Stocks Performance
DBV vs DAX Index

Loading
DBV
DAX Index
Add Stock
www.alphaspread.com

Performance Gap
DBV vs DAX Index

Loading
DBV
DAX Index
Difference
www.alphaspread.com

Performance By Year
DBV vs DAX Index

Loading
DBV
DAX Index
Add Stock

Competitors Performance
DBV Technologies SA vs Peers

DAX Index
DBV
ABBV
AMGN
GILD
VRTX
Add Stock

DBV Technologies SA
Glance View

Market Cap
191.5m EUR
Industry
Biotechnology

DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The company is headquartered in Montrouge, Ile-De-France. The company went IPO on 2012-03-29. The firm's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. The company dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The firm's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The firm operates one subsidiary DBV Technologies Inc. in the United States.

DBV Intrinsic Value
0.82 EUR
Overvaluation 41%
Intrinsic Value
Price
Back to Top